Assessing the global threat from Zika virus

See allHide authors and affiliations

Science  12 Aug 2016:
Vol. 353, Issue 6300, aaf8160
DOI: 10.1126/science.aaf8160

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. eLetters are not edited, proofread, or indexed.  Please read our Terms of Service before submitting your own eLetter.

Compose eLetter

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

  • RE: Global threat from Zika virus. Consider Ivermectin to reduce the transmission of Zika and other diseases by mosquitoes.

    Global threat from Zika virus. Consider Ivermectin to reduce the transmission of Zika and other diseases by mosquitoes.

    The impressive analysis of Justin Lessler et. al (Science 14 July 2016) motivates us to investigate every reasonable way to reduce the impact of Zika. The Nobel Prize winner antiparasitary medicine Ivermectin has achieved the reduction of about a third of transmissions of malaria in Africa thanks to its ectoparasitizide effect that kills the mosquitoes after they bite the patients.

    It has the potential to reduce the enormous impact of Zika, Chikungunya, Dengue and Malaria in Latin America and elsewhere if administered to the appropriate affected patients and family circle, a regular dose daily for four days, with minimal costs and minimal side effects. I propose this dosage since Aedes requires higher dose than Anopheles.

    This can be done together with the other known methods to reduce the propagation of mosquitos and the transmission of these diseases.

    Given the serious complications of Zika and the actual epidemic in Nicaragua, since the Zika test are not done rapidly, we start treatment based on the clinical manifestations in a pragmatically way, after ruling out Dengue or Chikungunya, to alleviate the symptoms and try to reduce the risk of posterior complications like Guillain Barré.

    I treat the symptoms with Cox 2 NSAIDs that have no effects in platelets, or paracetamol, antihistamines and antileukotriens, to impr...

    Show More
    Competing Interests: None declared.

Stay Connected to Science

Navigate This Article